Analgesics Market Size, Share, and Trends 2025 to 2034

Analgesics Market Size and Forecast 2025 to 2034

The global analgesics market was valued at USD 43.76 billion in 2024 and is anticipated to reach around USD 79.86 billion by 2034, expanding at a CAGR of 6.20% over the forecast period from 2025 to 2034. The market is growing due to the rising prevalence of chronic pain conditions, an increasing aging population, and greater demand for effective pain management solutions.

Market Highlights

• North America region accounted for 42% of revenue share in 2024.
• Asia Pacific region is expected to grow at a CAGR of 7.8% from 2025 to 2034.
• By drug type, the NSAID's segment is expected to reach at a CAGR of 4.5% from 2025 to 2034.
• By indication, surgical pain has held a revenue share of over 53.5% in 2024. However, the intravenous segment is expected to grow at a CAGR of 7.7% from 2025 to 2034.
• By type, the prescription segment accounted for 71% of revenue share in 2024.
• By route of administration, the oral segment has a 48% revenue share in 2024.

Market Overview

Analgesics, commonly referred to as painkillers or pain relievers, are medications that reduce pain without disturbing consciousness, altering sensory perception, or interrupting the conduction of nerve impulses. These medicines include acetaminophen, often known as paracetamol or APAP in North America, salicylates, a class of nonsteroidal anti-inflammatory medications (NSAIDs), and opioids including morphine and oxycodone. Physiological injuries, operations, phantom pains, inflammation, neuropathic diseases, and cancer therapies all cause pain, which is treated with analgesics. The strongest painkillers come in the form of opioid drugs, which are made from opium. They are often used to treat moderate to severe pain and are only accessible with a prescription. Contrarily, acetaminophen is used to make non-opioid medications rather than opium. Another group of medications called NSAIDs (non-steroidal anti-inflammatory drugs) is frequently used to alleviate mild to moderate pain.

What are the Major Trends in the Analgesics Market?

• Growing Preference for Non-Opioid Pain Management: Increasing concerns over opioid dependence and stricter prescribing regulations are driving demand for non-opioid analgesics, including NSAIDs, acetaminophen, and topical pain relief products.
• Rising Adoption of Topical and Transdermal Formulations: Consumers are increasingly opting for pain relief gels, creams, patches, and sprays that provide targeted treatment with fewer systemic side effects.
• Expansion of Over-the-Counter (OTC) Analgesics: The growing trend of self-medication, coupled with easy availability of OTC pain relief products through retail and online pharmacies, is boosting market growth.
• Innovation in Extended-Release and Combination Therapies: Pharmaceutical companies are developing long-acting formulations and combination analgesics to improve pain control, enhance patient compliance, and reduce dosing frequency.
• Increasing Use of Digital Health and AI in Pain Management: AI-powered diagnostics, wearable devices, and digital therapeutics are supporting personalized pain management, treatment monitoring, and medication adherence.
• Growing Demand for Biologic and Targeted Pain Therapies: Advances in biotechnology are encouraging the development of biologics, monoclonal antibodies, and gene-based therapies for chronic pain conditions and inflammatory disorders.
• Expansion of E-commerce and Online Pharmacies: The rapid growth of digital healthcare platforms and online pharmacies is improving patient access to analgesic medications and supporting market expansion globally.

Market Scope

Market Dynamics

Driver

• The analgesics market is driven by the rising incidence of chronic pain diseases, such as migraines, musculoskeletal ailments, arthritis, and pain following surgery. The market is still expanding due to the aging populations, which are more prone to pain-related conditions, more awareness of pain treatment, and easier access to both prescription and over-the-counter drugs. Additionally, more individuals are seeking pain reduction treatments thanks to increased healthcare spending and better diagnostic rates. Another factor driving market growth is the growing accessibility of pain management services in clinics, hospitals, and retail pharmacies.

Restraint

• The market faces challenges because of worries about the long-term usage and adverse effects of analgesic medications, especially opioids and other nonsteroidal anti-inflammatory medicines. Some painkillers may not be widely used due to regulatory limitations, addiction and dependency hazards, and growing scrutiny from healthcare authorities. Additionally, safety alerts and product recalls can have a detrimental impact on prescription practices and consumer confidence. In certain patient populations, the availability of alternative therapies like acupuncture and physical rehabilitation may also lessen reliance on prescription analgesics.

Opportunity

• The market for analgesics has enormous growth potential due to the development of safer and more focused pain management treatments. Innovative drug delivery methods, extended release formulations, personalized medicine, and non-opioid analgesics are opening up new ways for producers to meet unmet patient needs while lowering side effects. Treatment options should increase in the upcoming years due to growing research into biologics and new pain-modulating therapies. Additionally, growing consumer demand for self-medication and home healthcare products is creating new revenue streams for market players.

Segments Insights

By Drug Class

The Opioids Segment Dominated the Market in 2025

The opioids segment dominated the analgesics market with the largest share in 2025 due to their remarkable efficacy in treating moderate to severe pain brought on by trauma, cancer, surgery, and severe chronic illnesses. When quick and effective pain relief is needed in hospitals and specialized care settings, these medications are still the recommended choice. The extensive clinical application, well-established treatment guidelines, and accessibility in a variety of formulations all contribute to segment leadership. Opioids continue to play a major part in the treatment of acute and severe pain despite stricter regulations.

The NSAIDs segment is witnessing the fastest growth, owing to the growing need for pain relief options that don't involve opioids and have lower dependency risks. These medications are frequently used to treat inflammatory diseases, musculoskeletal conditions, headaches, and arthritis. The widespread availability of over-the-counter NSAIDs and consumers' growing preference for safer pain relief options are driving market expansion. Segment growth is also being supported by ongoing product innovations and better formulations.

By Indication

What Made Surgical Pain the Dominant Segment in the Markt in 2025?

The surgical pain segment dominated the market in 2025 because orthopedic, cardiovascular, cosmetic, and general surgery procedures are becoming more common worldwide. Analgesic drugs are in high demand because effective pain management is essential to the healing process following surgery. To enhance patient outcomes and shorten recovery times, hospitals and healthcare providers are placing an increasing emphasis on pain management procedures. Segment dominance is further strengthened by the rising number of inpatient and outpatient surgeries.

The neuropathic pain segment is expected to grow at a significant rate over the projection period because chronic neurological conditions and disorders related to the nerves are becoming more common. The need for specialized pain management is growing due to an increase in diabetic neuropathy, multiple sclerosis, and nerve injuries. Early detection and long-term treatment of nerve pain are becoming more and more important to medical professionals. The market is expanding in this segment due to developments in targeted therapies.

By Type

Why did the Prescription Segment Dominated the Market in 2025?

The prescription segment dominated the analgesic market in 2025 since a lot of moderate to severe pain conditions need specialized medication and treatment under a doctor's supervision. For chronic conditions requiring greater therapeutic efficacy, cancer pain, and post-surgical pain, prescription analgesics are widely used. For individualized pain management techniques, medical professionals still depend on prescription drugs. The segment's dominant position is further reinforced by the availability of cutting-edge formulations and combination treatments.

The OTC segment is growing rapidly due to self-medication becoming more popular among consumers, and pain relief products are easily accessible. Over-the-counter analgesics are commonly used to treat common conditions like headaches, fever, muscle soreness, and minor injuries. Product accessibility is being supported by growing networks of retail pharmacies and increased health consciousness. Additionally, e-commerce platforms are increasing the accessibility of over-the-counter pain relief products for customers.

By Pain Type

How did the Musculoskeletal Pain Segment Lead the market?

The musculoskeletal pain segment dominated the market in 2025 owing to the widespread occurrence of joint disorders, back pain, arthritis, and injuries sustained during sports. The number of patients in need of pain management has increased due to sedentary lifestyles, aging populations, and rising obesity rates. Analgesics are frequently bought or prescribed to treat these acute and chronic illnesses. Segment leadership is maintained by ongoing demand from both younger and older populations.

The neuropathic pain segment is the fastest growing due to chronic neurological conditions and disorders related to the nerves becoming more common. The demand for specialized pain treatments is rising due to an increase in cases of multiple sclerosis, diabetic neuropathy, and nerve injuries. Early diagnosis and long-term treatment of nerve pain are becoming increasingly important to medical professionals. The market is expanding in these sectors due to developments in targeted therapies.

By Application

The Internal Analgesics Segment Lead the Market in 2025?

The internal analgesics segment dominated the market in 2025 because a variety of acute and chronic pain conditions continue to be primarily treated with oral and injectable painkillers. These products are frequently used in clinics, hospitals, and home care settings to relieve systemic pain. Widespread adoption is supported by their extensive clinical acceptance and demonstrated efficacy. Market dominance is further reinforced by consistent product availability in both OTC and prescription categories.

The external analgesics segment is growing rapidly due to topical pain relief products like gels, creams, sprays, and patches becoming increasingly popular. These products reduce systemic side effects while providing localized treatment. Adoption is being accelerated by rising demand for noninvasive pain relief and sports injury treatments. Consumer acceptance is being further increased by new product developments and better formulations.

By Route of Administration

The Oral Segment Held a Major Market Share in 2025

The oral segment dominated the analgesics market while holding a major share in 2025 because of its affordability, ease of use, and high patient compliance. Hospitals, pharmacies, and internet resources make tablets, capsules, and liquid formulations widely prescribed and readily available. From minor discomfort to long-term illnesses, a variety of pain conditions can be effectively managed with oral analgesics. They are still the most popular option worldwide due to their simplicity in administration.

The transdermal segment is experiencing the fastest growth owing to the growing need for regulated and long-term drug delivery systems. While minimizing the gastrointestinal side effects that are frequently connected to oral medications, pain relief patches offer reliable therapeutic effects. These products are becoming increasingly popular among patients and medical professionals for the treatment of chronic pain. Technological developments in medication delivery and patch design are bolstering market expansion.

By Distribution Channel

What Made Hospital Pharmacies the Dominant Segment in 2025?

The hospital pharmacies segment dominated the analgesics market in 2025 because analgesics are frequently used in inpatient treatment settings, emergency rooms, and surgical procedures. Prescription painkillers are still primarily obtained from hospitals for severe and complicated pain conditions. Surgical procedures and hospital admissions are increasing, which sustains steady demand. Segment leadership is further enhanced by effective medication management and physician supervision.

The online pharmacies segment is growing rapidly as home delivery options and digital healthcare services are becoming increasingly popular among consumers. Pain relief products are now more widely available due to growing internet penetration of smartphone usage and e-commerce adoption. More product options and affordable prices are frequently available on online platforms. Online pharmacy channels are seeing an increase in purchases due to the growing acceptance of telemedicine.

Regional Insights

What Made North America the Dominant Region in the Market?

North America dominated the analgesics market in 2025 due to its high healthcare spending, sophisticated healthcare infrastructure, and robust access to pain management treatments. There is a steady need for both prescription and over-the-counter analgesics due to the high prevalence of chronic pain conditions in the area. Market leadership is further supported by the presence of significant industry players and ongoing investments in pharmaceutical research. Sustained market growth is also influenced by rising awareness of available pain management options.

• In January 2025, the U.S. Food and Drug Administration sanctioned Journavx (suzetrigine) 50 milligram oral tablets, a unique non-opioid analgesic, for the management of moderate to severe acute pain in adults. Journavx alleviates pain by focusing on a pain-signaling pathway that includes sodium channels in the peripheral nervous system, prior to the pain signals arriving at the brain.

U.S. Market Trends

The U.S. is the largest contributor to the North American analgesics market due to its advanced healthcare infrastructure, high prevalence of chronic pain conditions, and strong demand for both prescription and over-the-counter (OTC) pain medications. The country also benefits from substantial pharmaceutical research and development investments, widespread access to innovative pain management therapies, and a large aging population that requires long-term pain treatment. Additionally, the presence of leading pharmaceutical companies and well-established distribution networks further strengthens the U.S.'s dominant position in the regional market.

U.S. Analgesics Market Size and Growth 2025 to 2034

The U.S. analgesics market size accounted for USD 12.87 billion in 2024 and is projected to be worth around USD 23.93 billion by 2034, poised to grow at a CAGR of 6.40% from 2025 to 2034.

What Makes Asia Pacific the Fastest-Growing Region in the Market?

Asia Pacific is the fastest-growing region in the analgesics market due to its sizable patient base, growing healthcare spending, and expanding access to healthcare services. The demand for pain management products is rising due to an increase in musculoskeletal disorders, chronic diseases, and age-related conditions. Market growth is being aided by increasing health consciousness and pharmaceutical manufacturing capacity. Regional growth is still accelerating with increasing urbanization and better healthcare infrastructure.

China Market Trends

China is a major contributor to the Asia Pacific analgesics market due to its large population base, high prevalence of chronic diseases, and rapidly expanding healthcare infrastructure. Strong domestic pharmaceutical manufacturing capabilities and increasing production of both prescription and over-the-counter (OTC) analgesics further support market growth. Additionally, rising healthcare awareness, government initiatives to improve access to pain management treatments, and growing demand for affordable generic drugs are key factors driving China's dominance in the region.

India Market Trends

The retail expansion of pharmacies and low-cost over-the-counter drugs is advantageous to India's analgesics market. Demand is supported by swelling numbers of arthritis, chronic pain, and lifestyle-related diseases. The rising trend of self-medication and greater availability of low-cost pain relief products are also playing a key role in further supporting the market.

How is the Opportunistic Rise of Europe in the Analgesics Market?

Europe is expected to witness steady growth in the analgesics market during the forecast period, driven by the rising prevalence of chronic pain conditions, an aging population, and increasing demand for effective pain management therapies. Growing healthcare expenditure, widespread access to advanced pharmaceuticals, and strong regulatory support for innovative non-opioid pain treatments are further supporting market expansion. Additionally, increasing awareness of self-medication and the availability of over-the-counter (OTC) analgesics are contributing to sustained market growth across the region.

Germany Market Trends

Germany is a major contributor to the European analgesics market due to its well-established healthcare system, high burden of musculoskeletal disorders, and strong pharmaceutical manufacturing base. Rising adoption of non-opioid analgesics, increasing demand for topical pain relief products, and continued investment in pain management research are driving market growth in the country.

What Drives the Market in Latin America?

The Latin American analgesics market is growing steadily due to increasing cases of chronic diseases, sports injuries, and postoperative pain requiring effective pain management. Rising healthcare access, expanding pharmaceutical distribution networks, and growing consumer preference for OTC pain relief medications are supporting market growth. Furthermore, increasing healthcare investments and greater awareness of early pain treatment are expected to create new opportunities across the region.

Brazil Market Trends

Brazil represents the largest market in Latin America, driven by its large patient population, expanding healthcare infrastructure, and increasing demand for affordable analgesic medications. The growing availability of generic drugs and OTC pain relief products, along with rising healthcare spending, continues to support market expansion.

Why is the Analgesics Market in the Middle East & Africa Gaining Momentum?

The Middle East & Africa analgesics market is gaining momentum due to improving healthcare infrastructure, rising prevalence of chronic diseases and orthopedic conditions, and increasing demand for accessible pain management therapies. Growing government investments in healthcare, expanding pharmaceutical supply chains, and increasing awareness of pain management are contributing to market growth. Additionally, the increasing availability of OTC analgesics and the expansion of hospital and retail pharmacy networks are expected to further accelerate market development.

Saudi Arabia Market Trends

Saudi Arabia is a key contributor to the regional market, supported by rising healthcare expenditure, increasing incidence of chronic pain disorders, and continuous investments under healthcare modernization initiatives. The growing adoption of advanced pain management therapies, coupled with expanding hospital infrastructure and improved access to pharmaceutical products, is driving the country's analgesics market.

Competitive Landscape

The analgesics market is moderately fragmented, with both multinational pharmaceutical companies and generic manufacturers competing with each other on the basis of their product innovation and global distribution. Abbott has a strong standing with a wide portfolio and a strong R&D program, as do Pfizer Inc. and Eli Lilly & Company.

Emphasis is on non-opioid pharmacotherapy, advanced drug delivery systems, and personalized pain management solutions. Entry barriers due to regulatory requirements, patent protection, and high development costs. Going forward, the focus will be on safer analgesics, digital health integration, and new approaches to chronic pain treatments.

Analgesics Market Companies

• Abbott
• Pfizer Inc.
• Eli Lilly & Company
• Endo International plc
• F. Hoffmann-La Roche AG Bausch Health Companies Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson Private Limited
• GSK plc.
• Purdue Pharma L.P.

Recent Developments

• In January 2026, Pacira BioSciences entered a strategic partnership with LG Chem to commercialize EXPAREL, a long-acting non-opioid postsurgical analgesic, across selected Asia-Pacific markets. The agreement is expected to expand patient access to opioid-sparing pain therapies. (Source: https://www.nasdaq.com)
• In February 2026, Hikma Pharmaceuticals launched the authorized generic version of Nucynta (tapentadol) in the U.S. market, improving access to opioid analgesic treatments for acute pain management. The launch strengthens the company's pain management portfolio. (Source: https://www.hikma.com)
• In April 2026, Cumberland Pharmaceuticals received FDA approval for an expanded indication of Caldolor (ibuprofen injection) for postoperative pain management. The approval reinforces growing demand for non-opioid analgesic therapies in hospital settings.(Source: https://www.drugs.com)
• In May 2026, Viatris Inc. announced FDA acceptance of its New Drug Application for fast-acting meloxicam, a non-opioid therapy intended for moderate-to-severe acute pain treatment. The product is expected to broaden non-opioid pain management options.(Source: https://newsroom.viatris.com)
• In February 2026, Capsadyn, a non-burning capsaicin cream from Chorda Pharma Inc., is now available on Amazon and Capsadyn.com, offering consumers convenient access to effective pain relief without the burning sensation. (Source: https://www.prweb.com)
• In January 2025, Vertex Pharmaceuticals received U.S. FDA approval for Journavx (suzetrigine), the first new class of non-opioid pain medicine approved in more than 20 years for moderate-to-severe acute pain management. This development represents a major advancement in reducing reliance on opioid-based analgesics. (Source: https://www.axios.com)
• In August 2025, Ensysce Biosciences announced the initiation of a Phase III clinical trial for PF614, its next-generation opioid analgesic designed with abuse-deterrent and overdose-protection features. The program aims to provide safer pain management alternatives for severe pain patients. (Source: https://www.nasdaq.com)
• In September 2025, Maxwellia launched Naprosyn Pain Relief 250 mg gastro-resistant tablets, the UK's first over-the-counter naproxen medicine, previously a prescription drug for 40 years, making it their fifth reclassified medication. (Source: https://www.pharmacy.biz)

Segment Covered in the Report

By Drug Class

• Opioids
  • Morphine
  • Fentanyl
  • Codiene
  • Methadone
  • Meperidine
  • Oxycodone
  • Tramadol
  • Dextromethorphan
  • Buprenorphine
  • Others
• NSAIDs
• Local Anesthetics
• Acetaminophen

By Indication

• Surgical Pain
• Cancer Pain
• Neuropathic Pain
• Others

By Type

• Prescription
• OTC

By Pain Type

• Musculoskeletal Pain
• Surgical and Trauma Pain
• Cancer Pain
• Neuropathic Pain
• Migraine
• Obstetrical Pain
• Fibromyalgia
• Pain due to Burns
• Dental/Facial Pain
• Paediatric Pain
• Others

By Application

• Internal Analgesics
• External Analgesics

By Route of Administration

• Oral
• Parenteral
• Transdermal
• Others

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Drug Stores
• Online pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)